The webinar will feature presentations from Key Opinion Leaders (KOLs) Chiara Cremolini, MD, PhD (Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy) and Adam Brufsky, MD, PhD (University of Pittsburgh School of Medicine).

Dr. Cremolini will provide an expert data overview on the ASCO 2022 poster session: An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the phase II randomized AtezoTRIBE study. Subsequently, Dr. Brufsky and  Dr.Cremolini will participate in an expert fireside chat on assessing the tumor micro-environment to identify potential responders to immunotherapy in Colon and Breast Cancer.

A question and answer session will follow.